Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
NCT01432483 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2015-01-26
Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.
Conditions
Interventions
- DRUG
-
Denileukin diftitox (ONTAK)
Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
Sponsors & Collaborators
-
Eisai Inc.
lead INDUSTRY
Principal Investigators
-
Gary Palmer, MD · Eisai Inc.
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00923312 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
NCT06607393 ·Status: COMPLETED
-
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
NCT03520686 ·Status: TERMINATED ·Phase: PHASE3
-
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
NCT00066885 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
NCT00682981 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
NCT01846416 ·Status: COMPLETED ·Phase: PHASE2
-
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
NCT04691817 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Locally Advanced NSCLC Hyperfractionated RT
NCT03128008 ·Status: COMPLETED ·Phase: PHASE2
-
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
NCT04465942 ·Status: UNKNOWN
-
Taxotere-Enoxaparin-(ENOXA)-Study
NCT01058759 ·Status: TERMINATED ·Phase: PHASE3
-
Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
NCT03693547 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
NCT00386555 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
NCT01234038 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)
NCT00418743 ·Status: UNKNOWN
-
Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
NCT00322751 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
NCT00040638 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
NCT00258739 ·Status: COMPLETED ·Phase: PHASE2
-
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
NCT04648033 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
NCT01439568 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer
NCT00047801 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
NCT00216125 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
NCT04234113 ·Status: TERMINATED ·Phase: PHASE1
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
NCT05800587 ·Status: RECRUITING ·Phase: PHASE2
-
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
NCT02129699 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT00112346 ·Status: COMPLETED ·Phase: PHASE2